Thu, 2 July 2015
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.
Direct download: GRACEcast-337_ASCO_2015_Debating_EGFR_Inhibitors_Squamous_Patients.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT